Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS (Details Narrative)

v3.7.0.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended
Dec. 31, 2016
Aug. 31, 2016
Dec. 16, 2016
Jun. 30, 2016
Description for distribution and income receieved by the corporation Assigned to K4 30% of the distributions and income received by the Corporation from its investment in SOLX, Inc.      
Terms of conversion feature   At any time prior to the maturity date, the note is convertible into shares of common stock of the Company at a price per share equal to 90% of the closing bid price of the common stock during the 20 consecutive trading days immediately preceding such conversion.    
Interest rate   7.50%    
Description of interest rate computation   Interest will accrue at 7.5% computed on a 365-day basis    
Royality percentage of net revenue 5.00%      
John M Krohn [Member] | K4 [Member]        
Ownership, Percentage 50.00%      
Caretta Therapeutics, LLC [Member]        
K4 common membership units issued by the company     350,000  
Zika Therapeutics, LLC [Member]        
K4 common membership units issued by the company     200,000  
SMA Therapeutics, LLC [Member]        
K4 common membership units issued by the company     200,000  
Mr Arthur [Member]        
Convertible note   $ 20,000    
Common stock reserve for future issuance   6,000    
Shares issued upon conversion of convertible debt 54,054      
Description of exercise price

The warrant issued provides for the issuance of warrants to purchase that number of shares of common stock of the Company equal to 30% of the amount invested in the convertible notes based on the exercise price of the Warrants (the exercise price is defined as 110% of the closing bid price of the common stock of the Company on the six-month anniversary of the issuance date of the convertible note).

     
Dr. Agarwal [Member]        
Convertible note   $ 350,000    
Common stock reserve for future issuance   105,000    
Description of exercise price  

The warrant issued provides for the issuance of warrants to purchase that number of shares of common stock of the Company equal to 30% of the amount invested in the convertible notes based on the exercise price of the Warrants (the exercise price is defined as 110% of the closing bid price of the common stock of the Company on the six-month anniversary of the issuance date of the convertible note).

   
K4 Enterprise, LLC [Member]        
Loan payable       $ 560,751